Skip to main content

Table 4 Comparison of clinical outcomes between two longitudinal cohorts

From: Changes of antithrombotic prescription in atrial fibrillation patients with acute coronary syndrome or percutaneous coronary intervention and the subsequent impact on long-term outcomes: a longitudinal cohort study

Clinical Outcomes

Overall Cohort (N=121)

Cohort 2 vs. Cohort 1

P Value

Cohort 1 (N=35)

Cohort 2 (N=86)

Hazard ratio (95% CI)

Primary safety endpoint, N (%)

11 (31.4)

22 (25.6)

0.87 (0.42-1.80)

0.710

Major bleeding, N (%)

10 (28.6)

17 (19.8)

0.74 (0.34-1.62)

0.456

CRNMB, N (%)

1 (2.9)

5 (5.8)

2.16 (0.25-18.45)

0.483

Secondary efficacy endpoint, N (%)

7 (20.0)

17 (19.8)

0.96 (0.40-2.32)

0.930

All-cause death, N (%)

2 (5.7)

8 (9.3)

1.57 (0.33-7.41)

0.567

Stroke/SE, N (%)

1 (2.9)

4 (4.7)

1.60 (0.18-14.28)

0.676

Nonfatal MI, N (%)

2 (5.7)

2 (2.3)

0.39 (0.06-2.79)

0.350

Revascularization, N (%)

2 (5.7)

3 (3.5)

0.60 (0.10-3.59)

0.576